Thank you to New Jersey’s dynamic life sciences community for helping us celebrate the innovation coming from the Garden State during BioNJ’s 23rd Annual Dinner Meeting and Innovation Celebration that took place last week. The inspirational and moving evening set the stage for the important year ahead with so much happening on the national stage and a robust public policy agenda here in New Jersey.
Over the last week, there were a number of new FDA designations and approvals going to SCYNEXIS, Immunomedics, Bristol-Myers Squibb, Merck, Promius Pharma, Matinas BioPharma and Dr. Reddy’s Laboratories. See more below.
The New Jersey Economic Development Authority (EDA) announced that 213 investments were approved under the Angel Investor Tax Credit Program, representing the injection of more than $51 million of private capital into 28 companies in New Jersey’s biotechnology, technology and clean technology sectors.
Additionally, the New Jersey Health Foundation has committed $1 million for its next round of grant funding. Through its existing NJHF Research Grants program, this latest allocation will fund awards of up to $35,000 each for early stage research projects that demonstrate exciting potential and may lead to larger future grants from other organizations to further advance the research.
Plus, we are so pleased to welcome the newest companies to call New Jersey home and thank those who are expanding their presence within the State, including Nevakar LLC, Unichem Pharmaceuticals, Aralez Pharmaceuticals, Ascensia Diabetes Care and BAP Pharma.
Make sure to visit BioNJ’s newly designed website, www.BioNJ.org for the industry’s latest happenings as well as information on upcoming BioNJ events.